Home
Scholarly Works
Creatinine as a Measure of Lean Body Mass During...
Journal article

Creatinine as a Measure of Lean Body Mass During Treatment of Acute Lymphoblastic Leukemia in Childhood

Abstract

Protein energy malnutrition is well-recognized in children with acute leukemia and may result in loss of lean body mass (LBM) with attendant morbidities. Much of the LBM consists of skeletal muscle, the mass of which is reflected in urinary creatinine excretion. As accurate 24 hours urine collections are challenging in children, we investigated the prospect that serum creatinine concentration provides a measure of LBM. Eleven children with acute lymphoblastic leukemia were assessed at 7 time points (6-mo intervals) from diagnosis to 1 year after the completion of therapy. LBM was measured as fat-free mass by dual energy x-ray absorptiometry (DXA scans) and correlated with serum creatinine concentration and 24 hours urine creatinine excretion. As expected, there was a strong correlation between 24 hours urinary creatinine excretion and LBM from DXA scans (r=0.79, P<0.001). Serum creatinine concentration also correlated with LBM (r=0.52, P<0.001). Serum creatinine concentration provides a surrogate measure of LBM in children with acute lymphoblastic leukemia. This will be especially useful in countries with limited resources in which more sophisticated measures, such as DXA scans, are seldom available.

Authors

Morrison J; Nayiager T; Webber CE; Sala A; Barr R

Journal

Journal of Pediatric Hematology/Oncology, Vol. 33, No. 1, pp. e13–e16

Publisher

Wolters Kluwer

Publication Date

January 1, 2011

DOI

10.1097/mph.0b013e3181f46c0b

ISSN

1077-4114

Contact the Experts team